{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:30:19Z","timestamp":1789587019777,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"10549","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk AS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/s0140-6736(26)01022-6","type":"journal-article","created":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T21:34:02Z","timestamp":1780868042000},"page":"38-51","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cagrilintide\u2013semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study"],"prefix":"10.1016","volume":"408","author":[{"given":"Julio","family":"Rosenstock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana K","family":"Billings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Gajria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Giorgino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanna Borup","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klara R","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha K","family":"Thamattoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B","family":"Buse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay B","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(26)01022-6_bib1","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1177\/1479164116679775","article-title":"Gaps and barriers in the control of blood glucose in people with type 2 diabetes","volume":"14","author":"Blonde","year":"2017","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/S0140-6736(26)01022-6_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12226984","article-title":"Cardiovascular disease in diabetes and chronic kidney disease","volume":"12","author":"Swamy","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/S0140-6736(26)01022-6_bib3","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/S0140-6736(26)01022-6_bib4","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1056\/NEJMoa075392","article-title":"Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes","volume":"357","author":"Holman","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(26)01022-6_bib5","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1463-1326.2011.01413.x","article-title":"Weight and glycaemic control in type 2 diabetes: what is the outcome of insulin initiation?","volume":"13","author":"Watson","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/S0140-6736(26)01022-6_bib6","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.2337\/dc12-2258","article-title":"The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988\u20132010","volume":"36","author":"Stark Casagrande","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/S0140-6736(26)01022-6_bib7","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"issue":"suppl 1","key":"10.1016\/S0140-6736(26)01022-6_bib8","first-page":"S166","article-title":"8. Obesity and weight management for the prevention and treatment of diabetes: standards of care in diabetes\u20142026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"issue":"suppl 1","key":"10.1016\/S0140-6736(26)01022-6_bib9","first-page":"S183","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/S0140-6736(26)01022-6_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S0140-6736(26)01022-6_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/S0140-6736(26)01022-6_bib12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12933-026-03113-3","article-title":"Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"25","author":"Shokravi","year":"2026","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/S0140-6736(26)01022-6_bib13","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/dom.14765","article-title":"Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): a randomized, open-label, multinational, phase 3b trial","volume":"24","author":"Kellerer","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/S0140-6736(26)01022-6_bib14","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1001\/jama.2023.20294","article-title":"Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes: the SURPASS-6 randomized clinical trial","volume":"330","author":"Rosenstock","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/S0140-6736(26)01022-6_bib15","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b74 mg with once-weekly semaglutide 2\u00b74 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(26)01022-6_bib16","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(26)01022-6_bib20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(26)01022-6_bib21","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s00125-017-4289-0","article-title":"Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial","volume":"60","author":"Kapitza","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/S0140-6736(26)01022-6_bib22","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2\u00b74 mg for weight management: a randomised, controlled, phase 1b trial","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(26)01022-6_bib23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12933-021-01229-2","article-title":"The residual cardiorenal risk in type 2 diabetes","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/S0140-6736(26)01022-6_bib24","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(26)01022-6_bib25","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1056\/NEJMoa2502082","article-title":"Cagrilintide\u2013semaglutide in adults with overweight or obesity and type 2 diabetes","volume":"393","author":"Davies","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(26)01022-6_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(26)00126-9","article-title":"Efficacy and safety of once-weekly cagrilintide\u2013semaglutide in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study","author":"Aroda","year":"2026","journal-title":"Lancet Diabet Endocrinol"},{"key":"10.1016\/S0140-6736(26)01022-6_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(26)00125-7","article-title":"Cagrilintide\u2013semaglutide versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study","author":"Buse","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/S0140-6736(26)01022-6_bib28","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/bimj.201000239","article-title":"Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests","volume":"53","author":"Bretz","year":"2011","journal-title":"Biom J"},{"key":"10.1016\/S0140-6736(26)01022-6_bib29","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41366-020-00733-x","article-title":"Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data","volume":"45","author":"Wharton","year":"2021","journal-title":"Int J Obes"},{"key":"10.1016\/S0140-6736(26)01022-6_bib30","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1111\/dom.13804","article-title":"Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: the PIONEER 1 randomized clinical trial as an example","volume":"21","author":"Aroda","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/S0140-6736(26)01022-6_bib31","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s13300-022-01222-2","article-title":"Expert panel guidance and narrative review of treatment simplification of complex insulin regimens to improve outcomes in type 2 diabetes","volume":"13","author":"Jude","year":"2022","journal-title":"Diabetes Ther"},{"key":"10.1016\/S0140-6736(26)01022-6_bib32","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12902-016-0120-z","article-title":"Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials","volume":"16","author":"Erpeldinger","year":"2016","journal-title":"BMC Endocr Disord"},{"issue":"suppl 1","key":"10.1016\/S0140-6736(26)01022-6_bib33","first-page":"1","article-title":"Assessing cardiovascular safety and outcomes with the combination of cagrilintide and semaglutide (CagriSema): REDEFINE 3 randomised clinical trial baseline characteristics and methods","volume":"19","author":"Cavender","year":"2026","journal-title":"Obes Facts"},{"key":"10.1016\/S0140-6736(26)01022-6_bib34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/S0140-6736(26)01022-6_bib35","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s11892-015-0602-9","article-title":"\u03b2 cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in east Asians","volume":"15","author":"Yabe","year":"2015","journal-title":"Curr Diab Rep"},{"key":"10.1016\/S0140-6736(26)01022-6_bib36","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/dom.12129","article-title":"Treat-to-target trials: uses, interpretation and review of concepts","volume":"16","author":"Garber","year":"2014","journal-title":"Diabetes Obes Metab"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673626010226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673626010226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:23:17Z","timestamp":1784780597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673626010226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":33,"journal-issue":{"issue":"10549","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0140673626010226"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(26)01022-6","relation":{},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cagrilintide\u2013semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study","name":"articletitle","label":"Article Title"},{"value":"The Lancet","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(26)01022-6","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0140-6736(26)01074-3","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}